Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ascendis Pharma A/S price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ascendis Pharma A/S's price to sales ratio was 14.1× on Nov 11, 2026, against 17.3× a year earlier. Over the last 5 years it ranged from 12.2× to 431.6×, with a median of 24.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.1× | −3.0 |
| 2025 | Dec 31, 2025 | 17.2× | −6.4 |
| 2024 | Dec 31, 2024 | 23.5× | −18.5 |
| 2023 | Dec 29, 2023 | 42.1× | −151.7 |
| 2022 | Dec 30, 2022 | 193.7× | −237.9 |
| 2020 | Apr 30, 2020 | 431.6× | +155.0 |
| 2019 | Dec 31, 2019 | 276.6× | +40.1 |
| 2018 | Jan 31, 2018 | 236.5× | +44.3 |
| 2017 | Dec 29, 2017 | 192.2× | +136.0 |
| 2016 | Dec 30, 2016 | 56.2× | – |
See a number that looks wrong?